Novo Nordisk Escalates False Advertising Battle Against Eli Lilly with Motion for Preliminary Injunction
The commercial battle between the two giants of the GLP-1 obesity market, Novo Nordisk and Eli Lilly, has reached a critical legal juncture in federal court. Following its initial Lanham Act lawsuit filed on July 21, 2026, Novo Nordisk filed a motion for a preliminary injunction on July 24, 2026, in the United States District Court for the District of New Jersey. The motion seeks to temporarily block Eli Lilly from running national direct-to-consumer (DTC) advertising campaigns that compare the clinical efficacy of their respective drugs.
The Core Dispute: Outdated Clinical Comparisons
The dispute centers on Lilly's marketing campaigns for its obesity drug Zepbound and diabetes drug Mounjaro. Novo Nordisk alleges that Lilly’s advertisements are "false and materially misleading" because they rely on outdated clinical trials to claim superiority over Novo’s products. Specifically:
- Lilly's ads claim Zepbound produces "significantly more" weight loss than Wegovy.
- Lilly's ads claim Mounjaro reduces A1C "significantly more" than Ozempic.
Novo Nordisk argues these claims are deceptive under the Lanham Act because they selectively compare lower, outdated maintenance doses of Novo's medications against Lilly's highest doses1. The study cited by Lilly was conducted in 2021, prior to the FDA approval and market availability of Novo's highest maintenance doses, such as the Ozempic 2.0 mg dose. By omitting these newer, more effective doses from the comparison, Novo argues Lilly is deceiving millions of consumers into believing its drugs are vastly superior.
August 2026 Hearing and Reserved Decision
On August 28, 2026, the motion hearing for the preliminary injunction resumed in New Jersey federal court before U.S. District Judge Zahid N. Quraishi. After hearing arguments from both pharmaceutical giants, Judge Quraishi reserved decision on Novo Nordisk's motion.
Lilly continues to oppose the injunction vigorously, standing by its advertising as "truthful" and "transparent." Until Judge Quraishi issues his formal ruling, Eli Lilly is permitted to continue running the disputed comparative advertisements, leaving the marketing landscape highly volatile.
"Novo argues Lilly's advertisements are false and misleading under the Lanham Act as they create the impression of current, 'head-to-head' comparisons even though the studies cited do not include the latest FDA-approved doses of Novo Nordisk's medicines, the motion said." — MobiHealthNews, July 24, 2026
"Misleading advertisements that selectively compare lower doses of Novo Nordisk's medicines against higher doses of Lilly’s medicines, based on outdated studies, leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true..." — John F. Kuckelman, Senior VP and Group General Counsel at Novo Nordisk, quoted in MobiHealthNews
"Quraishi: Motion Hearing resumed on 8/28/2026 re 8 MOTION for Preliminary Injunction filed by NOVO NORDISK INC. Decision Reserved." — PacerMonitor Docket Entry, Case 3:26-cv-04023
-
An instance of In a saturated drug market, head-to-head superiority is manufactured by comparator selection. — The duopoly is litigating head-to-head superiority claims built on favorable comparator selection, exactly the manufactured-comparison battlefield the theme describes. ↩︎